$INSM earnings report

Total Company Revenues of $524.4 Million for the Third Quarter of 2026; BRINSUPRI revenues of $400.1 Million and ARIKAYCE revenues of $124.4 Million. AlphAI read INSMED's Third quarter 2026 filing as strong. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readINSM · Third quarter 2026 · ended September 30, 2026

Total Company Revenues of $524.4 Million for the Third Quarter of 2026; BRINSUPRI revenues of $400.1 Million and ARIKAYCE revenues of $124.4 Million.

✓Strong quarter

Total revenues increased 268% to $524.4 million, led by BRINSUPRI revenue of $400.1 million and 29% sequential BRINSUPRI growth. ARIKAYCE revenue increased 9%, the net loss narrowed to $100.3 million from $370.0 million, and the Company raised the low end of 2026 revenue guidance for both commercial products.

Revenue
$524M
268% y/y
ARIKAYCE U.S.
$75.5M
2% y/y
EPS · GAAP
$ (0.46 )

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenues, net, three months ended September 30GAAP$524.4M–268%
Product revenues, net, nine months ended September 30GAAP$1.26B–267%
ARIKAYCE total revenue, three months ended September 30GAAP$124.4M–9%
ARIKAYCE total revenue, nine months ended September 30GAAP$338.8M–8%
ARIKAYCE U.S. revenue, three months ended September 30GAAP$75.5M–2%
ARIKAYCE international revenue, three months ended September 30GAAP$48.9M–21%
ARIKAYCE U.S. revenue, nine months ended September 30GAAP$208.6M–1%
ARIKAYCE international revenue, nine months ended September 30GAAP$130.2M–21%
BRINSUPRI total revenue, three months ended September 30GAAP$400.1M29%NM
BRINSUPRI total revenue, nine months ended September 30GAAP$917.1M–NM
BRINSUPRI U.S. revenue, three months ended September 30GAAP$398.1M–NM
BRINSUPRI international revenue, three months ended September 30GAAP$2M–N/A
BRINSUPRI U.S. revenue, nine months ended September 30GAAP$913.8M–NM
BRINSUPRI international revenue, nine months ended September 30GAAP$3.3M–N/A
Total U.S. revenues, three months ended September 30GAAP$473.6M–364%
Total international revenues, three months ended September 30GAAP$50.8M–26%
Total U.S. revenues, nine months ended September 30GAAP$1.12B–378%
Total international revenues, nine months ended September 30GAAP$133.5M–24%
Cost of product revenues (excluding amortization of intangible assets), three months ended September 30GAAP$78.22M––
Cost of product revenues (excluding amortization of intangible assets), nine months ended September 30GAAP$192.8M––
Research and development, three months ended September 30GAAP$270.0M––
Research and development, nine months ended September 30GAAP$689.5M––
Selling, general and administrative, three months ended September 30GAAP$253.0M––
Selling, general and administrative, nine months ended September 30GAAP$747.8M––
Amortization of intangible assets, three months ended September 30GAAP$5.05M––
Amortization of intangible assets, nine months ended September 30GAAP$9.21M––
Change in fair value of contingent consideration liabilities, three months ended September 30GAAP$7.54M––
Change in fair value of contingent consideration liabilities, nine months ended September 30GAAP−$139.2M––
Total operating expenses, three months ended September 30GAAP$613.8M––
Total operating expenses, nine months ended September 30GAAP$1.50B––
Operating loss, three months ended September 30GAAP−$89.37M––
Operating loss, nine months ended September 30GAAP−$244.2M––
Investment income, three months ended September 30GAAP$11.07M––
Interest expense, three months ended September 30GAAP−$20.41M––
Loss before income taxes, three months ended September 30GAAP−$97.65M––
Provision for income taxes, three months ended September 30GAAP$2.67M––
Net loss, three months ended September 30GAAP−$100.3M––
Net loss, nine months ended September 30GAAP−$277.1M––
Basic and diluted net loss per share, three months ended September 30GAAP$ (0.46 )––
Basic and diluted net loss per share, nine months ended September 30GAAP$ (1.28 )––
Weighted average basic and diluted common shares outstanding, three months ended September 30GAAP218,788––
Weighted average basic and diluted common shares outstanding, nine months ended September 30GAAP217,215––

Segments

SegmentRevenueq/qy/y
ARIKAYCE U.S.ARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.$75.5M–2%
ARIKAYCE InternationalARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.$48.9M–21%
ARIKAYCE TotalPrimarily driven by strong growth in international markets.$124.4M–9%
BRINSUPRI U.S.BRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.$398.1M–NM
BRINSUPRI InternationalBRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.$2M–N/A
BRINSUPRI TotalDriven by strong growth in the U.S. market.$400.1M29%NM

Full-year 2026 outlook

  • NoteBRINSUPRI revenue guidance: $1.35 billion to $1.4 billion
  • NoteARIKAYCE revenue guidance: $460 million to $470 million
  • NotePeak revenues for BRINSUPRI: more than $7 billion
  • NotePeak revenues for TPIP: more than $6 billion
  • NotePeak revenues for ARIKAYCE: more than $1 billion
  • NoteSubmitting an average of one to two INDs per year from its pre-clinical research programs
  • NoteThe totality of its pre-clinical research programs will comprise less than 20% of overall expenditures

What drove it

  • BRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.
  • ARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.
  • Cost of product revenues as a percentage of revenues decreased in the third quarter of 2026 due to sales of BRINSUPRI, which has lower manufacturing costs than ARIKAYCE.
  • R&D expense increased due to manufacturing costs, clinical development and research costs primarily related to TPIP, and compensation, benefits, and stock-based compensation costs primarily related to higher headcount.
  • SG&A expense increased primarily due to professional fees, other external expenses, and compensation and benefit-related expenses driven by BRINSUPRI commercial activities.
  • Japan's MHLW approved BRINSUPRI Tablets 25 mg in August 2026, and Insmed launched the product in Japan in October 2026.
  • The FDA accepted the ARIKAYCE sNDA for MAC lung disease, granted Priority Review, and set a January 28, 2027 PDUFA target action date.

Concerns

  • The Company reported a net loss of $100.3 million for the third quarter of 2026 and a net loss of $277.1 million for the nine months ended September 30, 2026.
  • R&D expenses were $270.0 million and SG&A expenses were $253.0 million for the third quarter of 2026 as the Company funds TPIP development and BRINSUPRI commercialization.
  • ARIKAYCE U.S. revenue was $75.5 million, up 2% from the third quarter of 2025, while international revenue was $48.9 million, up 21%.
  • ARIKAYCE remains subject to an FDA accelerated approval indication in the United States, and the Company is seeking full approval and an expanded label.
  • The Company disclosed $544,862 of long-term debt and $146,231 of royalty financing agreement liabilities as of September 30, 2026.

What to watch

  • BRINSUPRI commercial execution in the U.S. and Japan following the Japan launch in October 2026.
  • FDA action on the ARIKAYCE sNDA for MAC lung disease by the January 28, 2027 PDUFA target action date.
  • Planned fourth-quarter 2026 submission of Phase 3 ENCORE data to Japan's PMDA to support a potential ARIKAYCE label expansion.
  • PALM-ILD enrollment progress, which exceeded 35% of patients, and the expectation to complete enrollment in the first half of 2028.
  • Initiation of the Phase 3 TPIP study in IPF anticipated in the first half of 2027.
  • Progression of INS1033, INS1148, INS1201, and INS1202 clinical programs.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $ 396,563
  • Marketable securities as of September 30, 2026: $ 750,063
  • Cash, cash equivalents, and marketable securities totaling approximately $1.1 billion as of September 30, 2026.
  • Accounts receivable as of September 30, 2026: $ 259,270
  • Inventory as of September 30, 2026: $ 163,946
  • Total assets as of September 30, 2026: $ 2,226,056
  • Debt, long-term as of September 30, 2026: $ 544,862
  • Current portion of royalty financing agreement as of September 30, 2026: $ 10,232
  • Royalty financing agreement as of September 30, 2026: $ 146,231
  • Total liabilities as of September 30, 2026: $ 1,499,842
  • Total shareholders' equity as of September 30, 2026: $ 726,214

Analysis

Insmed reported a sharp revenue step-up in the third quarter, with product revenues, net of $524.4 million versus $142.3 million in the third quarter of 2025. BRINSUPRI was the principal driver, generating $400.1 million of revenue, including $398.1 million in the U.S. The Company said global BRINSUPRI revenue grew 29% from the second quarter of 2026, driven by strong growth in the U.S. market. ARIKAYCE added $124.4 million of revenue, up 9% from the third quarter of 2025, with international revenue up 21% to $48.9 million and U.S. revenue up 2% to $75.5 million.

The revenue mix supported a substantial improvement in the operating result. Cost of product revenues excluding amortization of intangible assets was $78.2 million, and the Company said cost of product revenues as a percentage of revenues decreased because BRINSUPRI has lower manufacturing costs than ARIKAYCE. Operating loss narrowed to $89.4 million from $366.0 million, while net loss narrowed to $100.3 million, or $0.46 per share, from $370.0 million, or $1.75 per share.

Investment continues to rise alongside commercial expansion and pipeline development. R&D expense was $270.0 million, compared with $186.4 million, reflecting manufacturing costs, clinical development and research costs primarily related to TPIP, and higher headcount-related costs. SG&A expense was $253.0 million, compared with $186.4 million, primarily reflecting professional fees, external expenses, and personnel costs tied to BRINSUPRI commercial activities. The Company held approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2026, while long-term debt was $544.9 million.

Management raised the low end of 2026 guidance for both commercial products. BRINSUPRI guidance is now $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion, and ARIKAYCE guidance is now $460 million to $470 million, from $450 million to $470 million. The release also advances the commercial and regulatory agenda: BRINSUPRI launched in Japan in October 2026 after MHLW approval, while the FDA accepted the ARIKAYCE sNDA, granted Priority Review, and set a January 28, 2027 target action date.

Pipeline activity remains broad and spending-intensive. PALM-ILD enrollment exceeded 35%, with completion anticipated in the first half of 2028; PALM-PAH enrolled its first patient in July 2026; and PALM-PPF began in September 2026. Insmed continues to anticipate starting an IPF Phase 3 TPIP study in the first half of 2027. The key operating focus is whether BRINSUPRI growth, ARIKAYCE label expansion, and international commercialization continue to support the raised product revenue ranges while the Company funds multiple late-stage and early-stage programs.

Management, verbatim

The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline.

Will Lewis, Chair and Chief Executive Officer

BRINSUPRI’s U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market. This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products.

Will Lewis, Chair and Chief Executive Officer

Not in the filing

stated, not guessed
  • Gross margin
  • Operating margin
  • Net loss margin
  • Non-GAAP revenue, earnings, operating income, net income, or EPS
  • Operating cash flow
  • Capital expenditures
  • Free cash flow
  • Share repurchases
  • Dividends
  • Quarterly revenue guidance
  • Full-year total company revenue guidance
  • Gross-margin guidance
  • Operating-expense guidance
  • Tax-rate guidance
  • Prior-quarter values for the consolidated statement of net loss line items
  • A separately provided previous outlook section for formal actual-versus-prior-guidance comparisons

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readINSM · second quarter of 2026 · ended June 30, 2026

Total Company Revenues of $425.5 Million for the Second Quarter of 2026; BRINSUPRI Revenues of $309.2 Million; Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion

✓Strong quarter

Total revenues increased 296% to $425.5 million, led by $309.2 million of BRINSUPRI revenue and 49% sequential BRINSUPRI growth. The company substantially narrowed its net loss to $13.2 million from $321.7 million, raised BRINSUPRI revenue guidance, and reported approximately $1.2 billion of cash, cash equivalents, and marketable securities.

Revenue
$379M
451% y/y
ARIKAYCE U.S.
$70.2M
2% y/y
EPS · GAAP
$0.06

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenues, netGAAP$425.5M–296%
Total revenues U.S.GAAP$378.7M–451%
Total revenues InternationalGAAP$46.7M–21%
Cost of product revenues (excluding amortization of intangibles)GAAP$67.2M––
Research and development expensesGAAP$210M––
Selling, general and administrative expensesGAAP$247.5M––
Amortization of intangible assetsGAAP$2.08M––
Change in fair value of contingent consideration liabilitiesGAAP−99.76M––
Total operating expensesGAAP427.0M––
Operating lossGAAP−1.55M––
Investment incomeGAAP10.98M––
Interest expenseGAAP−20.27M––
Other (expense) income, netGAAP−531K––
Loss before income taxesGAAP−11.37M––
Provision for income taxesGAAP1.87M––
Net lossGAAP$13.2M––
Basic and diluted net loss per shareGAAP$0.06 per share––
Six-month product revenues, netGAAP$731.5M–265%
Six-month ARIKAYCE U.S. revenueGAAP$133.1M–<1%
Six-month ARIKAYCE International revenueGAAP$81.4M–21%
Six-month ARIKAYCE total revenueGAAP$214.4M–7%
Six-month BRINSUPRI U.S. revenueGAAP$515.7M–N/A
Six-month BRINSUPRI International revenueGAAP$1.3M–N/A
Six-month BRINSUPRI total revenueGAAP$517M–N/A
Six-month total revenues U.S.GAAP$648.8M–388%
Six-month total revenues InternationalGAAP$82.6M–23%
Six-month cost of product revenues (excluding amortization of intangible assets)GAAP114.6M––
Six-month research and developmentGAAP419.5M––
Six-month selling, general and administrativeGAAP494.7M––
Six-month amortization of intangible assetsGAAP4.16M––
Six-month change in fair value of contingent consideration liabilitiesGAAP−146.7M––
Six-month total operating expensesGAAP886.3M––
Six-month operating lossGAAP−154.9M––
Six-month investment incomeGAAP23.02M––
Six-month interest expenseGAAP−40.35M––
Six-month other (expense) income, netGAAP−1.27M––
Six-month loss before income taxesGAAP−173.5M––
Six-month provision for income taxesGAAP3.33M––
Six-month net lossGAAP−$176.8M––

Segments

SegmentRevenueq/qy/y
ARIKAYCE U.S.Not stated.$70.2M–2%
ARIKAYCE InternationalStrong growth in international markets.$46.1M–19%
ARIKAYCE TotalPrimarily driven by strong growth in international markets.$116.3M–8%
BRINSUPRI U.S.Strong growth in the U.S. market.$308.6M–N/A
BRINSUPRI InternationalNot stated.$600K–N/A
BRINSUPRI TotalDriven by strong growth in the U.S. market.$309.2M49%N/A
Total Revenues U.S.BRINSUPRI U.S. revenue was $308.6 million.$378.7M–451%
Total Revenues InternationalARIKAYCE international revenue was $46.1 million.$46.7M–21%

full-year 2026 outlook

  • NoteBRINSUPRI revenues: $1.25 billion to $1.40 billion
  • NoteARIKAYCE revenues: $450 million to $470 million
  • NoteAverage of one to two INDs per year from its pre-clinical research programs
  • NoteThe totality of its pre-clinical research programs will comprise less than 20% of overall expenditures
  • NotePeak revenue estimate for BRINSUPRI: more than $7 billion
  • NotePeak revenue estimate for TPIP: more than $6 billion
  • NotePeak revenue estimate for ARIKAYCE: more than $1 billion
  • NotePeak revenue estimate for the three lead programs: more than $14 billion total

What drove it

  • BRINSUPRI global revenue grew 49% in the second quarter of 2026 compared to the first quarter of 2026, driven by strong growth in the U.S. market.
  • ARIKAYCE global revenue grew 8% compared to the second quarter of 2025, primarily driven by strong growth in international markets.
  • Cost of product revenues as a percentage of revenues decreased due to sales of BRINSUPRI, which has lower manufacturing costs than ARIKAYCE.
  • R&D expense increased primarily from compensation and benefit-related expenses, stock-based compensation associated with higher headcount, and clinical development and research costs primarily related to TPIP.
  • SG&A expense increased primarily from professional fees, other external expenses, and compensation and benefit-related expenses driven by BRINSUPRI commercial activities.

Concerns

  • R&D expenses were $210.0 million and SG&A expenses were $247.5 million as the company funds TPIP development and BRINSUPRI commercial activities.
  • The company reported a net loss of $13.2 million for the second quarter of 2026.
  • Insmed continues to evaluate the potential effect of evolving U.S. policies on the timing for future potential international commercial launches.
  • The company plans continued investment across BRINSUPRI, ARIKAYCE, four Phase 3 TPIP programs, INS1148, INS1201, INS1202, INS1033, and pre-clinical research programs.

What to watch

  • A regulatory decision for brensocatib in non-cystic fibrosis bronchiectasis in Japan anticipated in the second half of 2026.
  • Review of Phase 3b ENCORE data with the PMDA in the second half of 2026 to support a potential ARIKAYCE label expansion in Japan.
  • Potential ARIKAYCE label expansion in the U.S. for newly diagnosed patients with MAC lung disease following the July 2026 sNDA submission.
  • Initiation of the Phase 3 TPIP study in progressive pulmonary fibrosis anticipated in the second half of 2026.
  • Initiation of the Phase 3 TPIP study in idiopathic pulmonary fibrosis anticipated in the first half of 2027.
  • Initiation of a Phase 1 trial of INS1033 in healthy volunteers planned for the third quarter of 2026.

Balance sheet and cash flow

  • As of June 30, 2026, cash, cash equivalents, and marketable securities totaled approximately $1.2 billion.
  • Investment income was 10,979 (in thousands) for the second quarter of 2026.
  • Interest expense was (20,273) (in thousands) for the second quarter of 2026.

Analysis

Insmed reported a sharp expansion in second-quarter revenue, with product revenues, net of $425.5 million, up 296% from $107.4 million. The principal driver was BRINSUPRI, which generated $309.2 million, including $308.6 million in the U.S., and grew 49% from the first quarter of 2026. ARIKAYCE contributed $116.3 million, up 8% from the prior-year quarter, as international revenue increased 19% to $46.1 million while U.S. revenue increased 2% to $70.2 million.

The increased BRINSUPRI contribution affected the cost structure. Cost of product revenues rose to $67.2 million from $28.1 million along with higher product revenue, but the company said cost of product revenues as a percentage of revenue decreased because BRINSUPRI has lower manufacturing costs than ARIKAYCE. The operating loss narrowed to $1.5 million from $312.9 million, and net loss narrowed to $13.2 million from $321.7 million. The quarter also included a $(99,760) thousand change in fair value of contingent consideration liabilities, compared with 59,000 thousand in the prior-year quarter.

Operating investment remains substantial. R&D expense rose to $210.0 million from $177.2 million, reflecting higher headcount-related costs and clinical development and research costs primarily related to TPIP. SG&A increased to $247.5 million from $154.8 million, driven by professional fees, external expenses, and higher headcount-related costs associated with BRINSUPRI commercial activities. Insmed ended the period with approximately $1.2 billion in cash, cash equivalents, and marketable securities.

Management raised full-year 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion from prior guidance of at least $1 billion, while reiterating ARIKAYCE guidance of $450 million to $470 million. The company also raised its peak revenue estimates for BRINSUPRI to more than $7 billion and TPIP to more than $6 billion, while maintaining more than $1 billion for ARIKAYCE. Execution items include a potential Japan decision for brensocatib in the second half of 2026, ARIKAYCE U.S. and Japan label-expansion work, and further TPIP Phase 3 study starts.

The period demonstrates that BRINSUPRI commercial uptake has rapidly reshaped revenue mix and reduced the reported operating loss, while ARIKAYCE continues to grow internationally. The key financial tradeoff remains the company’s planned expansion of commercial spending and clinical investment across its pipeline. Management specifically cited evolving U.S. policies as a potential factor affecting the timing of future potential international launches.

Management, verbatim

The U.S. BRINSUPRI launch continues to be met with significant enthusiasm and demand from patients and physicians.

Will Lewis, Chair and Chief Executive Officer of Insmed

We now expect that our three lead programs will generate more than $14 billion in combined peak sales.

Will Lewis, Chair and Chief Executive Officer of Insmed

Not in the filing

stated, not guessed
  • Gross profit and gross margin
  • Non-GAAP financial metrics, including non-GAAP operating income, non-GAAP net income, and non-GAAP EPS
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Debt balance
  • Share repurchases and dividends
  • Second-quarter basic and diluted weighted-average shares outstanding
  • Six-month basic and diluted net loss per share, as the filing text is truncated before the complete figure
  • Prior-quarter values for financial-statement line items other than BRINSUPRI revenue growth
  • A prior outlook section from the previous release for formal guidance-versus-actual comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about INSM earnings dates

When is INSMED's next earnings date?
AlphAI has no date for INSM yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.